

## Dosing Recommendations for Anti-Virals used for Prophylaxis and Treatment of Influenza in ESRD Patients

Both Oseltamivir (Tamiflu(r)) and Zanamavir (Relenza(r)) are almost 100% eliminated by the kidneys; however, there is no dosage adjustment in kidney failure for Zanamavir because it is inhaled and most of the dose is not absorbed systemically.

Oseltamivir requires dosage adjustment but the company does not give guidelines for dialysis patients. The company suggests the following for adult patients with a CrCL between 10-30 mL/min.

---

From Micromedex(r):

### 1.3.2 Dosage in Renal Failure

#### A) Oseltamivir Phosphate

1) For the treatment of influenza, the recommended dose of oseltamivir in patients with a creatinine clearance between 10 and 30 milliliters/minute (mL/min) is 75 milligrams (mg) once daily for 5 days. For prophylaxis of influenza, the recommended dose for patients with a creatinine clearance between 10 and 30 mL/min is 75 mg every other day or 30 mg once daily. No data are available in patients with a creatinine clearance below 10 mL/min (Prod Info TAMIFLU(R) oral capsules, suspension, 2008).

Dosage forms available: 30 mg, 45 mg and 75 mg capsules and oral powder for suspension (12 mg/mL)

---

Oseltamivir is dialyzable. It would probably be reasonable to administer the same dosages in HD and PD patients as for CrCL of 10-30 mL/min, knowing that both HD and PD will remove some of the drug. HD patients should have their doses administered after HD on dialysis days.

Since there are no data on oseltamivir dosage adjustments in HD and PD patients, HD or PD patients should be monitored closely by health care providers and their caregivers for signs of toxicity.

Common side effects include abdominal pain, nausea, vomiting

Serious but less common side effects include cardiac dysrhythmia, gastrointestinal hemorrhage, hemorrhagic colitis, hepatitis, seizures, abnormal behavior and delirium

*Disclaimer: The absence of typographical and other errors cannot be guaranteed. Use of these dosage guidelines indicates acknowledgement that Wendy St. Peter will not be held responsible for any loss or injury, including death, sustained in connection with, or as a result of, the use of these guidelines.*

Wendy L. St. Peter, Pharm.D., FCCP, BCPS Associate Professor, College of Pharmacy University of Minnesota and United States Renal Data System Chronic Disease Research Group  
914 S. 8th Street, Suite D-406  
Minneapolis, MN 55404  
Phone: 612-347-7752 (HCMC-primary, VM)  
612-625-5848 (U of MN-don't leave VM)  
Fax: 612-347-5980

Reviewed: 06-2011